NCT05142475View on ClinicalTrials.gov

Study on TIL for the Treatment of Advanced Breast Cancer

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 19, 2021

Primary Completion Date

December 20, 2024

Study Completion Date

December 20, 2025

Conditions
Breast CancerTreatment Side EffectsAdvanced Breast CancerEffects of Immunotherapy
Interventions
BIOLOGICAL

Tumor Infiltrating Lymphocytes (TIL)

Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.

Trial Locations (1)

Unknown

RECRUITING

Shanghai Tenth People's Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai 10th People's Hospital

OTHER

lead

Shanghai Juncell Therapeutics

INDUSTRY